Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7787]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
What does the Association of European Cancer Leagues (ECL) do?
Dr Wendy Yared - Director, Association of European Cancer Leagues (ECL)
What does the Association of European Cancer Leagues (ECL) do? ( Dr Wendy Yared - Director, Association of European Cancer Leagues (ECL) )
26 Oct 2016
Coming of age for CDK 4/6 inhibitors: Welcome and interactive session
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Welcome and interactive session ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
What are CDKs?
Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
What are CDKs? ( Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy )
26 Oct 2016
CDK clinical trial results, benefit, side effects and costs
Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy
CDK clinical trial results, benefit, side effects and costs ( Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy )
26 Oct 2016
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant...
Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting ( Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA )
26 Oct 2016
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers
Dr Sibylle Loibl - German Breast Cancer Group
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers ( Dr Sibylle Loibl - German Breast Cancer Group )
26 Oct 2016
Coming of age for CDK 4/6 inhibitors: Interactive session and close
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Interactive session and close ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
Biomarkers of sensitivity and resistance
Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
26 Oct 2016
Editor's ESMO 2016 roundup
Prof Gordon McVie - Editor in Chief, ecancer
Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )
24 Oct 2016
Abiraterone in patients with recurrent epithelial ovarian cancer
Dr Susanna Banerjee - The Royal Marsden, London, UK
Abiraterone in patients with recurrent epithelial ovarian cancer ( Dr Susanna Banerjee - The Royal Marsden, London, UK )
24 Oct 2016
Fatigue in men with castration resistant prostate cancer treated with...
Dr Simon Chowdhury - Guy's Hospital, London, UK
Fatigue in men with castration resistant prostate cancer treated with enzalutamide ( Dr Simon Chowdhury - Guy's Hospital, London, UK )
21 Oct 2016
CDK4/6 inhibition: PALOMA2 versus MONALEESA2
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
17 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation